Evidence map›Paper›PMID 41736014›Full record

ArticleThrombosis journal2026

Multifactorial thrombotic risk in Evans syndrome: a case report and review of the literature.

Hande Nur Erolmez, Semih Eker, Fakiha Siddiqui, Ayse Nilgun Kul, Gulbuz Sezgin, Jawed Fareed, Bulent Kantarcioglu

Abstract read
In one paragraph

Article in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hande Nur ErolmezDepartment of Family Medicine, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.ORCID http://orcid.org/0009-0004-3791-9157
Semih EkerDepartment of Internal Medicine, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Fakiha SiddiquiUCAM - Universidad Católica San Antonio de Murcia, Murcia, Spain.ORCID http://orcid.org/0000-0002-2219-7049
Ayse Nilgun KulDivision of Hematology, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, Department of Internal Medicine, University of Health Sciences, Namik Kemal Cad. No:54, Istanbul, Sancaktepe, 34785, Turkey.ORCID http://orcid.org/0000-0003-1806-2261
Gulbuz SezginDepartment of Internal Medicine, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-0774-2766
Jawed FareedHealth Science Division, Cardiovascular Research Institute, Department of Pathology & Laboratory Medicine, Loyola University Chicago, Maywood, IL, USA.ORCID http://orcid.org/0000-0003-3465-2499
Bulent KantarciogluHealth Science Division, Cardiovascular Research Institute, Department of Pathology & Laboratory Medicine, Loyola University Chicago, Maywood, IL, USA. bulentkantarcioglu@gmail.com.ORCID http://orcid.org/0000-0003-3060-721X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvans syndrome (ES) is a rare autoimmune disorder characterized by the coexistence of immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA). Beyond bleeding and infections complications, ES is increasingly recognized as a prothrombotic condition, particularly in the presence of multiple risk factors such as hemolysis, thrombocytopenia-related immune dysregulation, splenectomy, and exposure to thrombopoietin receptor agonists. However, the importance of antiphospholipid antibodies is less well established in ES patients. CASE PRESENTATION: We report the case of a 53-year-old male with a long-standing history of AIHA, later complicated by ITP and diagnosed as ES, who presented with acute deep vein thrombosis of the right lower extremity despite severe thrombocytopenia. His medical history was notable for prior splenectomy, recurrent venous thromboembolic events, cerebral venous sinus thrombosis, and recent exposure to eltrombopag. Laboratory evaluation revealed evidence of compensated hemolysis and persistent lupus anticoagulant positivity, while other antiphospholipid antibodies were negative. Due to profound thrombocytopenia, anticoagulation was initiated following platelet count recovery achieved with intravenous immunoglobulin and corticosteroids. Platelet counts were subsequently maintained with eltrombopag, allowing continuation of therapeutic anticoagulation without bleeding complications.

conclusionsThis case highlights the complex interplay between thrombosis and thrombocytopenia in ES. Rather than a single etiologic factor, thrombotic events in ES appear to result from the accumulation of multiple prothrombotic conditions, including immune cytopenias, prior splenectomy, and treatment-related factors, with antiphospholipid antibodies potentially acting as an additional risk amplifier. Recognition of this multifactorial risk profile is essential for tailored management and prevention of thrombotic complications in patients with ES.

Indexed as

Antiphospholipid syndromeDeep vein thrombosisEltrombopagEvans syndromeImmune thrombocytopeniaSplenectomyThrombosis

Identifiers

PMID41736014
PMCPMC13040922

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.